TW200716152A - Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture - Google Patents
Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufactureInfo
- Publication number
- TW200716152A TW200716152A TW095110860A TW95110860A TW200716152A TW 200716152 A TW200716152 A TW 200716152A TW 095110860 A TW095110860 A TW 095110860A TW 95110860 A TW95110860 A TW 95110860A TW 200716152 A TW200716152 A TW 200716152A
- Authority
- TW
- Taiwan
- Prior art keywords
- substituted
- ethylendiamines
- medicaments
- manufacture
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06026—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 0 or 1 carbon atom, i.e. Gly or Ala
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06008—Dipeptides with the first amino acid being neutral
- C07K5/06017—Dipeptides with the first amino acid being neutral and aliphatic
- C07K5/06034—Dipeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/06—Dipeptides
- C07K5/06191—Dipeptides containing heteroatoms different from O, S, or N
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
- C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0802—Tripeptides with the first amino acid being neutral
- C07K5/0812—Tripeptides with the first amino acid being neutral and aromatic or cycloaliphatic
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
- C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
- C07K5/08—Tripeptides
- C07K5/0821—Tripeptides with the first amino acid being heterocyclic, e.g. His, Pro, Trp
Landscapes
- Chemical & Material Sciences (AREA)
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Biochemistry (AREA)
- Biophysics (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Molecular Biology (AREA)
- Genetics & Genomics (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Animal Behavior & Ethology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- General Chemical & Material Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Engineering & Computer Science (AREA)
- Pharmacology & Pharmacy (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Neurosurgery (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Vascular Medicine (AREA)
- Urology & Nephrology (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Emergency Medicine (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Endocrinology (AREA)
- Oncology (AREA)
- Orthopedic Medicine & Surgery (AREA)
- Physical Education & Sports Medicine (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP05006939 | 2005-03-30 |
Publications (1)
Publication Number | Publication Date |
---|---|
TW200716152A true TW200716152A (en) | 2007-05-01 |
Family
ID=36545049
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
TW095110860A TW200716152A (en) | 2005-03-30 | 2006-03-29 | Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture |
Country Status (7)
Country | Link |
---|---|
US (3) | US7713961B2 (zh) |
EP (1) | EP1866034A1 (zh) |
JP (1) | JP2008534541A (zh) |
AR (1) | AR056862A1 (zh) |
CA (1) | CA2603404A1 (zh) |
TW (1) | TW200716152A (zh) |
WO (1) | WO2006103038A1 (zh) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CA2603404A1 (en) * | 2005-03-30 | 2006-10-05 | Boehringer Ingelheim International Gmbh | Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture |
CA2617294A1 (en) * | 2005-08-03 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii |
WO2007017510A2 (de) * | 2005-08-11 | 2007-02-15 | Boehringer Ingelheim International Gmbh | Isophthalsäurediamide zur behandlung der alzheimer erkrankung |
CA2618019A1 (en) * | 2005-08-11 | 2007-02-15 | Boehringer Ingelheim International Gmbh | Compounds for the treatment of alzheimer's disease |
CA2618481A1 (en) * | 2005-08-11 | 2007-02-15 | Boehringer Ingelheim International Gmbh | Compounds for treating alzheimer's disease |
CA2618013A1 (en) * | 2005-08-11 | 2007-02-15 | Boehringer Ingelheim International Gmbh | Beta-secretase inhibitors for use in the treatment of alzheimer's disease |
EP2349308A4 (en) | 2008-10-10 | 2012-09-12 | Purdue Research Foundation | COMPOUNDS FOR THE TREATMENT OF ALZHEIMER'S DISEASE |
WO2010059953A1 (en) | 2008-11-20 | 2010-05-27 | Purdue Research Foundation | Quinazoline inhibitors of bace 1 and methods of using |
US8859590B2 (en) | 2008-12-05 | 2014-10-14 | Purdue Research Foundation | Inhibitors of BACE1 and methods for treating Alzheimer's disease |
WO2011044057A1 (en) * | 2009-10-05 | 2011-04-14 | Comentis, Inc. | Sulfonamido pyrrolidine compounds which inhibit beta-secretase activity and methods of use thereof |
US20140066488A1 (en) * | 2012-08-30 | 2014-03-06 | Purdue Research Foundation | Inhibitors of Memapsin 2 Cleavage for the Treatment of Alzheimer's Disease |
Family Cites Families (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CZ184194A3 (en) | 1993-08-09 | 1995-03-15 | Lilly Co Eli | Aspartylprotease inhibitor and method of identifying thereof |
US7087399B1 (en) | 1999-05-13 | 2006-08-08 | Scios, Inc. | β-secretase and modulation of β-secretase activity |
US6545127B1 (en) | 1999-06-28 | 2003-04-08 | Oklahoma Medical Research Foundation | Catalytically active recombinant memapsin and methods of use thereof |
US20050130941A1 (en) * | 2001-06-08 | 2005-06-16 | Heinrich Schostarez | Methods of treating alzheimer's disease |
EP1453516A2 (de) | 2001-10-17 | 2004-09-08 | Boehringer Ingelheim Pharma GmbH & Co.KG | 5-substituierte 4-amino-2-phenylamino-pyrimdinderivate und ihre verwendung als beta-amyloid modulatoren |
WO2003057721A2 (en) * | 2002-01-04 | 2003-07-17 | Elan Pharmaceuticals, Inc. | Substituted amino carboxamides for the treatment of alzheimer's disease |
JP2006501282A (ja) * | 2002-09-27 | 2006-01-12 | イーラン ファーマスーティカルズ、インコーポレイテッド | アルツハイマー病治療のための化合物 |
EP1562897B1 (en) * | 2002-11-12 | 2009-09-16 | Merck & Co., Inc. | Phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease |
US20050090449A1 (en) | 2003-05-13 | 2005-04-28 | Boehringer Ingelheim International Gmbh | Novel statine derivatives for the treatment of Alzheimer's disease |
EP1641748B1 (en) * | 2003-06-30 | 2013-08-28 | Merck Sharp & Dohme Corp. | N-alkyl phenylcarboxamide beta-secretase inhibitors for the treatment of alzheimer s disease |
WO2005110422A2 (en) | 2004-05-19 | 2005-11-24 | Boehringer Ingelheim International Gmbh | Treatment of diseases associated with altered level of amyloid beta peptides |
WO2005113582A1 (en) | 2004-05-22 | 2005-12-01 | Boehringer Ingelheim International Gmbh | Substituted ethane-1,2-diamines for the treatment of alzheimer's disease |
WO2006050862A1 (en) | 2004-11-10 | 2006-05-18 | Boehringer Ingelheim International Gmbh | Statine derivatives for the treatment of alzheimer's disease |
WO2006050861A2 (en) | 2004-11-10 | 2006-05-18 | Boehringer Ingelheim International Gmbh | Statine derivatives for the treatment of alzheimer's disease |
CA2603404A1 (en) * | 2005-03-30 | 2006-10-05 | Boehringer Ingelheim International Gmbh | Substituted 1,2-ethylendiamines, medicaments comprising said compound; their use and their method of manufacture |
CA2617294A1 (en) | 2005-08-03 | 2007-02-08 | Boehringer Ingelheim International Gmbh | Substituted ethane-1,2-diamines for the treatment of alzheimer's disease ii |
CA2618019A1 (en) | 2005-08-11 | 2007-02-15 | Boehringer Ingelheim International Gmbh | Compounds for the treatment of alzheimer's disease |
-
2006
- 2006-03-27 CA CA002603404A patent/CA2603404A1/en not_active Abandoned
- 2006-03-27 EP EP06723747A patent/EP1866034A1/en not_active Withdrawn
- 2006-03-27 JP JP2008503415A patent/JP2008534541A/ja active Pending
- 2006-03-27 WO PCT/EP2006/002769 patent/WO2006103038A1/en not_active Application Discontinuation
- 2006-03-29 TW TW095110860A patent/TW200716152A/zh unknown
- 2006-03-29 AR ARP060101206A patent/AR056862A1/es not_active Application Discontinuation
- 2006-03-30 US US11/278,059 patent/US7713961B2/en active Active
-
2009
- 2009-07-29 US US12/511,474 patent/US20090325940A1/en not_active Abandoned
-
2010
- 2010-04-13 US US12/759,167 patent/US20100204160A1/en not_active Abandoned
Also Published As
Publication number | Publication date |
---|---|
US20060223759A1 (en) | 2006-10-05 |
WO2006103038A1 (en) | 2006-10-05 |
EP1866034A1 (en) | 2007-12-19 |
JP2008534541A (ja) | 2008-08-28 |
AR056862A1 (es) | 2007-10-31 |
CA2603404A1 (en) | 2006-10-05 |
US7713961B2 (en) | 2010-05-11 |
US20090325940A1 (en) | 2009-12-31 |
US20100204160A1 (en) | 2010-08-12 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
TW200716152A (en) | Substituted 1,2-ethylendiamines, medicaments comprising said compound, their use and their method of manufacture | |
NL300933I2 (nl) | Letermovir | |
RS20050361A (en) | Novel medicament for the treatment of chronic obstructive pulmonary diseases | |
TW200738242A (en) | Dihydropteridinones in the treatment of respiratory diseases | |
MX2007003031A (es) | Compuestos heteroarilo para uso como betamimeticos en el tratamiento de enfermedades de vias respiratorias. | |
NO20063275L (no) | Anvendelse av substituerte 2-aminotetraliner for forebyggende behandling av Parkinsons sykdom | |
EA200401114A2 (ru) | Замещённые гидроксиэтиламины | |
DK1689721T3 (da) | Aminopyrazolderivater som GSK-3-ihibitorer | |
BRPI0412851A (pt) | benzamidazóis de n-metila-substituìdos | |
TW200604196A (en) | New quinuclidine derivatives and pharmaceutical compositions comprising them | |
TW200630374A (en) | Thiazolyldihydroindazoles | |
WO2009007300A3 (en) | Substituted amino-quinazolinones, medicaments comprising said compound, their use and their method of manufacture | |
WO2005037798A3 (en) | Amide or thiomide derivatives and their use in the treatment of pain | |
IL183636A0 (en) | Quinoline derivative, use and production thereof, and drug containing the same | |
TW200640911A (en) | Novel, long acting betamimetics for the treatment of respiratory diseases | |
WO2007017511A3 (de) | Verbindungen zur behandlung der alzheimer erkrankung | |
WO2006050861A3 (en) | Statine derivatives for the treatment of alzheimer's disease | |
ATE409480T1 (de) | Pyrazoloä3,4-büpyridin-6-one als gsk-3 inhibitoren | |
MY146802A (en) | Novel drugs for treating respiratory diseases | |
CY1110401T1 (el) | Παραγωγα των 1-φαινυλαλκανοκαρβοξυλικων οξεων για την αντιμετωπιση των νευροεκφυλιστικων νοσων | |
WO2007017510A3 (de) | Isophthalsäurediamide zur behandlung der alzheimer erkrankung | |
ATE524171T1 (de) | Verwendung von 2-(2-nitro-4- trifluormethylbenzoyl)-1,3-cyclohexandion bei der behandlung der parkinson-krankheit | |
ATE407126T1 (de) | Herstellung von (s)-4-fluormethyl-dihydro-furan-2-on | |
SE0400708D0 (sv) | New compounds and use thereof | |
WO2008023003A8 (de) | Arzneimittelkombinationen zur behandlung von atemwegserkrankungen |